Literature DB >> 14663483

Role of PML and the PML-nuclear body in the control of programmed cell death.

Rosa Bernardi1, Pier Paolo Pandolfi.   

Abstract

PML is a tumor suppressor implicated in leukemia and cancer pathogenesis. PML epitomizes a multiprotein nuclear structure, the PML-nuclear body (PML-NB), whose proper formation and function depends on PML. Studies in knockout (KO) mice and cells unraveled an essential pleiotropic role for PML in multiple p53-dependent and -independent apoptotic pathways. As a result, Pml(-/-) mice and cells are protected from apoptosis triggered by a number of stimuli such as ionizing radiation, interferon, ceramide, Fas and TNF. It is becoming apparent that PML and the PML-NB act as molecular hubs for the induction and/or reinforcement of programmed cell death through a selective and dynamic regulation of proapoptotic transcriptional events. In addition, recent observations propose a role for PML in checkpoint responses upon DNA damage. Moreover, PML and the PML-NB have also been implicated in the control of genomic stability and DNA repair. Here, we will discuss the molecular mechanisms by which PML regulates these processes and the implication of these findings for cancer pathogenesis and therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14663483     DOI: 10.1038/sj.onc.1207106

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  69 in total

1.  Apoptin nucleocytoplasmic shuttling is required for cell type-specific localization, apoptosis, and recruitment of the anaphase-promoting complex/cyclosome to PML bodies.

Authors:  Destin W Heilman; Jose G Teodoro; Michael R Green
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

2.  The adenoviral E1B 55-kilodalton protein controls expression of immune response genes but not p53-dependent transcription.

Authors:  Daniel L Miller; Brenden Rickards; Michael Mashiba; Wenying Huang; S J Flint
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

3.  SUMO conjugation to the matrix attachment region-binding protein, special AT-rich sequence-binding protein-1 (SATB1), targets SATB1 to promyelocytic nuclear bodies where it undergoes caspase cleavage.

Authors:  Joseph-Anthony T Tan; Yujie Sun; Jing Song; Yuan Chen; Theodore G Krontiris; Linda K Durrin
Journal:  J Biol Chem       Date:  2008-04-11       Impact factor: 5.157

4.  Herpes simplex virus 1 ubiquitin ligase ICP0 interacts with PML isoform I and induces its SUMO-independent degradation.

Authors:  Delphine Cuchet-Lourenço; Emilia Vanni; Mandy Glass; Anne Orr; Roger D Everett
Journal:  J Virol       Date:  2012-08-08       Impact factor: 5.103

Review 5.  The role of PML in the control of apoptotic cell fate: a new key player at ER-mitochondria sites.

Authors:  P Pinton; C Giorgi; P P Pandolfi
Journal:  Cell Death Differ       Date:  2011-04-08       Impact factor: 15.828

Review 6.  Nuclear microenvironment in cancer diagnosis and treatment.

Authors:  Rossanna C Pezo; Robert H Singer
Journal:  J Cell Biochem       Date:  2008-08-15       Impact factor: 4.429

Review 7.  Intrinsic host restriction factors of human cytomegalovirus replication and mechanisms of viral escape.

Authors:  Santo Landolfo; Marco De Andrea; Valentina Dell'Oste; Francesca Gugliesi
Journal:  World J Virol       Date:  2016-08-12

8.  The human promyelocytic leukemia protein is a tumor suppressor for murine skin carcinogenesis.

Authors:  Victoria M Virador; Rafael E Flores-Obando; Adam Berry; Rinal Patel; Julia Zakhari; Yu-Chien Lo; Kathryn Strain; Joanna Anders; Christophe Cataisson; Laura A Hansen; Stuart H Yuspa
Journal:  Mol Carcinog       Date:  2009-07       Impact factor: 4.784

Review 9.  "Where, O death, is thy sting?" A brief review of apoptosis biology.

Authors:  Andrew H Wyllie
Journal:  Mol Neurobiol       Date:  2010-06-16       Impact factor: 5.590

10.  Activation of NF-kB pathway by virus infection requires Rb expression.

Authors:  Maria A Garcia; Pedro Gallego; Michela Campagna; José González-Santamaría; Gloria Martínez; Laura Marcos-Villar; Anxo Vidal; Mariano Esteban; Carmen Rivas
Journal:  PLoS One       Date:  2009-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.